20/20 BioLabs Reports Third Quarter 2026 Financial Results and Recent Business Updates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
20/20 BioLabs (Nasdaq: AIDX) reported third-quarter revenue of $380,216, down from the prior-year quarter as firefighter screening program timing affected testing. Gross margin fell to 25.5% from 34.7%. Net loss was $1,375,091, versus $825,539 a year earlier and $1.51 million in Q2 2026.
Nine-month revenue fell to $1,464,162 from $1,506,859, while OneTest revenue rose 4.1% to $1.36 million. Nine-month net loss widened to $5,056,270 from $2,431,050. Cash reached $3,633,711 at September 30, with no outstanding borrowings, following $6.0 million in Series E preferred financing.
Vermont signed a two-year OneTest Premium contract covering approximately 4,500 firefighters; the company expects revenue contributions in Q4 2026. A new royalty-based laboratory franchise model and planned technology licensing in 2027 aim to expand distribution.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSeries E preferred financing completed during the first half raised $6.0 million. 2.2× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Vermont signed a two-year screening contract covering approximately 4,500 firefighters; revenue contributions are expected in Q4 2026.
- Moderate pointNine-month OneTest revenue increased 4.1% to $1.36 million, primarily driven by Maryland firefighter screening.
- Moderate pointNine-month OneTest gross profit rose 15.6% to $0.45 million; margin expanded to 32.8% from 29.5%.
- Moderate pointNon-cancelable customer contracts entered during the first nine months totaled $1.30 million. 48% of market cap
9 minor points
- Minor pointCash increased to $3,633,711 at September 30, 2026, from $1,025,987 at year-end 2025.
- Minor pointOutstanding borrowings were zero at September 30, 2026.
- Minor pointThird-quarter loss per common share narrowed to $0.12 from $0.17 a year earlier.
- Minor pointNine-month gross margin increased to 31.7% from 31.5% a year earlier.
- Minor pointThird-quarter other income was $14,806, versus other expense of $25,366 a year earlier.
- Minor pointMaryland firefighter screening continued, with 18 fire-department groups awarded more than $520,000 in grants.
- Minor point. Forward-looking: it has not happened yet and may not happen.A new royalty-based laboratory franchise model is intended to expand OneTest distribution through regional laboratories.
- Minor point. Forward-looking: it has not happened yet and may not happen.Technology licensing to U.S. and international laboratories is planned to begin in 2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.The company targets FDA authorization and Medicare reimbursement for OneTest for Cancer by the end of 2028.
Negative
- Major pointNine-month net loss widened to $5,056,270 from $2,431,050 a year earlier.
- Major pointCommon shares outstanding increased to 13,367,204 from 5,442,249 at year-end 2025, diluting existing holders.
- Moderate pointThird-quarter revenue declined to $380,216 from $417,979 a year earlier.
- Moderate pointThird-quarter gross profit fell to $96,873 from $145,066; margin declined to 25.5% from 34.7%.
- Moderate pointThird-quarter operating expenses reached $1,486,770, versus $945,239 a year earlier, but declined 4.0% sequentially.
- Moderate pointThird-quarter net loss widened to $1,375,091 from $825,539 a year earlier, but narrowed from $1.51 million sequentially.
- Moderate pointNine-month revenue declined to $1,464,162 from $1,506,859 a year earlier.
- Moderate pointNine-month operating expenses increased to $4,541,960 from $2,892,149 a year earlier.
- Moderate pointNine-month other expense increased to $978,794 from $13,025 a year earlier.
- Moderate pointNine-month operating cash use increased to $2,806,849 from $1,408,053 a year earlier.
7 minor points
- Minor pointThird-quarter OneTest revenue fell to $0.35 million from $0.36 million a year earlier.
- Minor pointNine-month gross profit declined to $464,484 from $474,124 a year earlier.
- Minor pointNine-month loss per common share widened to $0.62 from $0.50 a year earlier.
- Minor pointSeries E convertible preferred stock creates potential dilution; 5,015 shares were outstanding at September 30, 2026.
- Minor pointNine-month offering costs totaled $822,573.
- Minor pointNine-month preferred stock dividends totaled $304,295, versus none a year earlier.
- Minor pointNine-month deemed dividends on warrant modifications totaled $1,124,676, versus none a year earlier.
News Explained
At
Key Figures
- Third-quarter revenue
- $0.38 million vs. $0.42 million
- Three months ended September 30, 2026, versus prior-year period
- OneTest revenue
- $1.36 million, increased 4.1%
- First nine months of 2026
- OneTest gross margin
- 32.8% vs. 29.5%
- First nine months of 2026, versus prior-year period
- Third-quarter gross margin
- 25.5% vs. 34.7%
- Three months ended September 30, 2026, versus prior-year period
- Nine-month net loss
- $5.06 million vs. $2.43 million
- First nine months of 2026, versus prior-year period
- Cash and borrowings
- $3.63 million in cash; no outstanding borrowings
- As of September 30, 2026
- Vermont screening contract
- Two years; approximately 4,500 firefighters
- Executed statewide OneTest Premium cancer screening contract
- Non-cancelable customer contracts
- $1.30 million
- Entered during the first nine months of 2026
Previous Earnings Reports
-
OneTest revenue and gross margin expanded, while quarterly revenue rose year over year.
-
First-quarter revenue declined year over year, and the company reported a larger net loss.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
clia regulatory
convertible notes financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
OneTest™ Revenue Increased
Vermont Executes Two-Year Firefighter Cancer Screening Contract with Testing Expected to Contribute Revenue in Q4
New Laboratory Franchise Model and 2027 Licensing Plans Aim to Broaden OneTest™ Distribution
Cash of
GAITHERSBURG, Md., Nov. 16, 2026 (GLOBE NEWSWIRE) -- 20/20 BioLabs, Inc. (Nasdaq: AIDX) (“20/20 BioLabs” or the “Company”), an early market entrant in AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases, today reported its financial and operational results for the third quarter ended September 30, 2026.
Third Quarter and Recent Operational Highlights
- OneTest™ revenue increased
4.1% to$1.36 million for the first nine months of 2026, representing92.8% of total revenue. - OneTest™ gross profit increased
15.6% to$0.45 million for the first nine months of 2026, with gross margin expanding to32.8% from29.5% . - Third quarter revenue was
$0.38 million , compared to$0.42 million in the prior year period, reflecting the timing of firefighter cancer screening programs. - Vermont executed a two-year contract specifying OneTest™ Premium for its statewide cancer screening program covering approximately 4,500 firefighters. Testing is expected to begin contributing to revenue in Q4 2026.
- Continued OneTest™ testing through Maryland's state-funded firefighter cancer screening program, with 18 groups of fire departments awarded more than
$520,000 in grants. - Introduced a OneTest™ laboratory franchise model to expand distribution through regional laboratories under a royalty-based structure.
- Announced plans to begin licensing its patented protein tumor marker testing technology to laboratories in the U.S. and internationally in 2027.
- Entered into
$1.30 million of non-cancelable customer contracts during the first nine months of 2026. - Cash and cash equivalents totaled
$3.63 million as of September 30, 2026, with no outstanding borrowings.
Management Commentary
President and Chief Executive Officer Jonathan Cohen commented, “OneTest™ revenue grew
“We are also working on new ways to reach more customers. Our franchise model would allow established regional laboratories to offer OneTest™ in their markets, without requiring us to build a national sales force. We have received preliminary interest from laboratories in the United States and plan to begin licensing our protein tumor marker approach to clinical laboratories in 2027.”
“With more than 25,000 firefighters screened to date, we are continuing to build the real-world evidence to support our regulatory strategy. We believe recent developments in the MCED testing industry are encouraging, and we remain focused on our goal of obtaining FDA authorization and Medicare reimbursement for OneTest™ for Cancer by the end of 2028,” concluded Cohen.
Chief Financial Officer Alan Bergman added, “We ended the third quarter with
“Gross margin was lower this quarter due to reduced testing volume, but our laboratory has the capacity to support additional testing without a corresponding increase in certain operating costs. As testing under the Vermont contract and other programs increases, we expect to benefit from better utilization of our existing laboratory capacity while continuing to manage expenses,” concluded Bergman.
Third Quarter 2026 Financial Results
Total revenue for the three months ended September 30, 2026 was
Total cost of revenue was
Gross profit was
Operating expenses were
Total other income, net, was
Net loss was
Cash and cash equivalents totaled
First Nine Months 2026 Financial Results
Total revenue for the nine months ended September 30, 2026 was
Gross profit was
Total operating expenses were
Net loss was
About 20/20 BioLabs
20/20 BioLabs, Inc. (Nasdaq: AIDX) develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. The Company offers two families of lab tests under the OneTest brand. OneTest™ for Cancer is a multi-cancer early detection blood test and OneTest™ for Longevity measures inflammatory biomarkers and is commercially available. OneTest’s tests are designed to be affordable and accessible and can be conveniently utilized at home using new, upper-arm capillary collection devices as an alternative to traditional venipuncture. Tests are run in the Company’s College of American Pathologists (CAP) accredited, Clinical Laboratory Improvement Amendments (CLIA) licensed laboratory in Gaithersburg, Maryland.
For more information visit https://2020biolabs.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about our goals and strategies; our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures; growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with; fluctuations in general economic and business conditions in the market in which we operate; and relevant government policies and regulations relating to our industry.
In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under Item 1A “Risk Factors” included in our Annual Report on Form 10-K for the year ended December 31, 2025 filed with the Securities and Exchange Commission, or the SEC, on March 31, 2026 and elsewhere in our filings with the SEC. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.
In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
The forward-looking statements made in this press release relate only to events or information as of the date on which the statements are made in this press release. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.
Investor Relations
Chris Tyson
MZ Group
Direct: 949-491-8235
AIDX@mzgroup.us
| 20/20 BIOLABS, INC. CONDENSED BALANCE SHEETS (UNAUDITED) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 3,633,711 | $ | 1,025,987 | ||||
| Accounts receivable, net | 173,985 | 199,954 | ||||||
| Inventory | 102,568 | 116,217 | ||||||
| Prepaid expenses and other current assets | 119,525 | 128,975 | ||||||
| Total current assets | 4,029,789 | 1,471,133 | ||||||
| License agreement, net | 259,893 | 271,143 | ||||||
| Property and equipment, net | 24,525 | 56,677 | ||||||
| Intangible asset, net | 205,168 | 202,264 | ||||||
| Right-of-use assets, net | 475,670 | 605,289 | ||||||
| Deferred financing costs | - | 1,507,794 | ||||||
| Other assets | 23,057 | 23,057 | ||||||
| Total assets | $ | 5,018,102 | $ | 4,137,357 | ||||
| Liabilities and Stockholders’ Equity (Deficit) | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,045,819 | $ | 868,545 | ||||
| Accrued liabilities | 642,335 | 785,784 | ||||||
| Accrued dividends – Series E convertible preferred stock | 128,441 | - | ||||||
| Deferred revenue – current | 478,937 | 414,871 | ||||||
| Derivative liability – current | - | 143,382 | ||||||
| Convertible notes payable – current | - | 74,611 | ||||||
| Operating lease liability – current | 195,848 | 175,948 | ||||||
| Total current liabilities | 2,491,380 | 2,463,141 | ||||||
| Long-term liabilities: | ||||||||
| Convertible notes payable, net | - | 619,355 | ||||||
| Deferred revenue – long-term | 29,372 | 41,816 | ||||||
| Derivative liabilities – long-term | - | 543,545 | ||||||
| Operating lease liability – long term | 329,847 | 488,725 | ||||||
| Total long-term liabilities | 359,219 | 1,693,441 | ||||||
| Total liabilities | 2,850,599 | 4,156,582 | ||||||
| Commitments and contingencies (Note 9) | - | - | ||||||
| Contingently redeemable convertible preferred stock: | ||||||||
| Series E convertible preferred stock, | 1,556,307 | - | ||||||
| Stockholders’ equity (deficit): | ||||||||
| Series D preferred stock, | - | 1,016 | ||||||
| Series C preferred stock, | - | 12,040 | ||||||
| Series B preferred stock, | - | 14,715 | ||||||
| Series A-2 preferred stock, | - | 4,424 | ||||||
| Series A-1 preferred stock, | - | 6,515 | ||||||
| Series A preferred stock, | - | 8,464 | ||||||
| Common stock, | 133,672 | 54,422 | ||||||
| Additional paid-in capital | 38,781,013 | 33,126,398 | ||||||
| Accumulated deficit | (38,303,489 | ) | (33,247,219 | ) | ||||
| Total stockholders’ equity (deficit) | 611,196 | (19,225 | ) | |||||
| Total liabilities, contingently redeemable preferred stock and stockholders’ equity (deficit) | $ | 5,018,102 | $ | 4,137,357 | ||||
| 20/20 BIOLABS, INC. CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenues | $ | 380,216 | $ | 417,979 | $ | 1,464,162 | $ | 1,506,859 | ||||||||
| Cost of revenues | 283,343 | 272,913 | 999,678 | 1,032,735 | ||||||||||||
| Gross profit | 96,873 | 145,066 | 464,484 | 474,124 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Sales, general and administrative | 1,363,385 | 814,179 | 4,007,461 | 2,430,134 | ||||||||||||
| Research and development | 123,385 | 131,060 | 534,499 | 462,015 | ||||||||||||
| Total operating expenses | 1,486,770 | 945,239 | 4,541,960 | 2,892,149 | ||||||||||||
| Operating loss | (1,389,897 | ) | (800,173 | ) | (4,077,476 | ) | (2,418,025 | ) | ||||||||
| Other (expense) income: | ||||||||||||||||
| Interest expense | - | (29,547 | ) | (539,253 | ) | (31,222 | ) | |||||||||
| Interest income | 14,806 | 4,181 | 35,935 | 18,312 | ||||||||||||
| Loss on change in fair value of warrant liability | - | - | (148,766 | ) | - | |||||||||||
| Loss on issuance of convertible note | - | - | (326,595 | ) | - | |||||||||||
| Other expense, net | - | - | (115 | ) | (115 | ) | ||||||||||
| Total other (expense) income | 14,806 | (25,366 | ) | (978,794 | ) | (13,025 | ) | |||||||||
| Provision for income taxes | - | - | - | - | ||||||||||||
| Net loss | (1,375,091 | ) | (825,539 | ) | (5,056,270 | ) | (2,431,050 | ) | ||||||||
| Deemed dividend on warrant modifications | - | - | (1,124,676 | ) | - | |||||||||||
| Preferred stock dividends | (128,441 | ) | - | (304,295 | ) | - | ||||||||||
| Net loss attributable to common stockholders | $ | (1,503,532 | ) | $ | (825,539 | ) | $ | (6,485,241 | ) | $ | (2,431,050 | ) | ||||
| Basic and diluted net loss per common share | $ | (0.12 | ) | $ | (0.17 | ) | $ | (0.62 | ) | $ | (0.50 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 12,958,114 | 4,849,770 | 10,484,242 | 4,849,770 | ||||||||||||
| 20/20 BIOLABS, INC. CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) | ||||||||
| Nine Months Ended September 30, | ||||||||
| 2026 | 2025 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (5,056,270 | ) | $ | (2,431,050 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 34,601 | 48,743 | ||||||
| Stock based compensation | 710,137 | 388,950 | ||||||
| Amortization of license fees | 18,750 | 16,875 | ||||||
| Issuance of common stock for services | 283,595 | - | ||||||
| Loss on issuance of convertible note | 326,595 | - | ||||||
| Amortization of right-of-use assets, net of liabilities | (9,359 | ) | (5,516 | ) | ||||
| Amortization of debt discount | 515,583 | 17,238 | ||||||
| Change in fair value of derivative liability | 148,766 | - | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts receivable | 25,969 | (1,601 | ) | |||||
| Inventory | 13,649 | (7,598 | ) | |||||
| Prepaid expenses and other assets | 9,450 | (22,605 | ) | |||||
| Accounts payable | 254,847 | 256,081 | ||||||
| Accrued liabilities | (134,784 | ) | 250,109 | |||||
| Settlement liability | - | 80,000 | ||||||
| Interest payable | - | 13,984 | ||||||
| Deferred revenue | 51,622 | (11,663 | ) | |||||
| Net cash used in operating activities | (2,806,849 | ) | (1,408,053 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Purchases of intangible assets, including patents | (5,354 | ) | - | |||||
| License agreement | (7,500 | ) | - | |||||
| Net cash used in investing activities | (12,854 | ) | - | |||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from issuance of convertible notes payable | 250,000 | 576,561 | ||||||
| Proceeds from issuance of series D preferred stock | - | 192,338 | ||||||
| Proceeds from issuance of series E convertible preferred stock | 6,000,000 | - | ||||||
| Offering costs | (822,573 | ) | - | |||||
| Net cash provided by financing activities | 5,427,427 | 768,899 | ||||||
| Increase (decrease) in cash and cash equivalents | 2,607,724 | (639,154 | ) | |||||
| Cash and cash equivalents, beginning of period | 1,025,987 | 1,784,009 | ||||||
| Cash and cash equivalents, end of period | $ | 3,633,711 | $ | 1,144,855 | ||||
| Supplemental disclosures of cash flow information: | ||||||||
| Cash paid for interest | $ | - | $ | - | ||||
| Cash paid for income taxes | $ | - | $ | - | ||||
| Non-cash disclosures of cash flow information: | ||||||||
| Conversion of preferred stock to common stock | $ | 393,154 | $ | - | ||||
| Deferred offering costs – issuance of common stock and warrants as offering costs | $ | 3,654,057 | $ | 452,736 | ||||
| Accrued dividends on series E convertible preferred stock | $ | 128,441 | $ | - | ||||
| Relief of accounts payable through the issuance of common stock | $ | 77,574 | $ | - | ||||
| Deemed dividend on warrant modifications | $ | 1,124,676 | $ | - | ||||
| Issuance of preferred stock for dividends on series E convertible preferred stock | $ | 175,854 | $ | - | ||||
| Derivative liabilities recognized as debt discounts | $ | 541,199 | $ | 152,384 | ||||
| Derivative liabilities reclassified to equity | $ | 1,381,124 | $ | - | ||||
| Conversion of convertible notes payable and accrued interest to common stock | $ | 834,812 | $ | - | ||||
| Conversion of convertible notes payable and accrued interest to series E convertible preferred stock | $ | 583,197 | $ | - | ||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were 20/20 BioLabs' third-quarter 2026 financial results?
20/20 BioLabs reported revenue of $380,216 and a net loss of $1,375,091 for the quarter ended September 30, 2026. A year earlier, revenue was $417,979 and net loss was $825,539. Gross margin declined to 25.5% from 34.7%.
When will 20/20 BioLabs' Vermont firefighter screening contract contribute revenue?
The company expects Vermont testing to begin contributing revenue in Q4 2026. Vermont executed a two-year contract specifying OneTest Premium for its statewide cancer screening program covering approximately 4,500 firefighters.
Why did 20/20 BioLabs' firefighter screening timing affect third-quarter revenue?
Maryland completed a substantial portion of its testing in the second quarter, while Vermont's program start shifted into the fourth quarter, the company said. This timing reduced third-quarter testing activity.